BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37953192)

  • 41. Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.
    Gao Q; Liu Y; Aypar U; Baik J; Londono D; Sun X; Zhang J; Zhang Y; Roshal M
    Cytometry B Clin Cytom; 2023 Jul; 104(4):279-293. PubMed ID: 36999235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How I investigate minimal residual disease in acute lymphoblastic leukemia.
    Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
    Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
    Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry.
    Cherian S; Soma LA
    Am J Clin Pathol; 2021 Jan; 155(1):38-54. PubMed ID: 33236071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.
    Chiaretti S; Messina M; Della Starza I; Piciocchi A; Cafforio L; Cavalli M; Taherinasab A; Ansuinelli M; Elia L; Albertini Petroni G; La Starza R; Canichella M; Lauretti A; Puzzolo MC; Pierini V; Santoro A; Spinelli O; Apicella V; Capria S; Di Raimondo F; De Fabritiis P; Papayannidis C; Candoni A; Cairoli R; Cerrano M; Fracchiolla N; Mattei D; Cattaneo C; Vitale A; Crea E; Fazi P; Mecucci C; Rambaldi A; Guarini A; Bassan R; Foà R
    Haematologica; 2021 Jun; 106(6):1559-1568. PubMed ID: 32467145
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
    Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
    Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transcriptome Sequencing Allows Comprehensive Genomic Characterization of Pediatric B-Acute Lymphoblastic Leukemia in an Academic Clinical Laboratory.
    Hu Z; Kovach AE; Yellapantula V; Ostrow D; Doan A; Ji J; Schmidt RJ; Gu Z; Bhojwani D; Raca G
    J Mol Diagn; 2024 Jan; 26(1):49-60. PubMed ID: 37981088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses.
    Kline KAF; Kallen ME; Duong VH; Law JY
    Curr Hematol Malig Rep; 2021 Oct; 16(5):384-393. PubMed ID: 34417955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.
    Choi JK; Mead PE
    Clin Lab Med; 2021 Sep; 41(3):485-495. PubMed ID: 34304777
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
    Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients.
    Yokota S; Hansen-Hagge TE; Ludwig WD; Reiter A; Raghavachar A; Kleihauer E; Bartram CR
    Blood; 1991 Jan; 77(2):331-9. PubMed ID: 1824678
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia.
    Liu X; Zou Y; Chen X; Wang S; Guo Y; Yang W; Zhang L; Chen Y; Zhang Y; Zhu X
    Leuk Lymphoma; 2020 Dec; 61(14):3460-3467. PubMed ID: 32779947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.
    Šálek C; Folber F; Froňková E; Pecherková P; Jelínková H; Hrabovský Š; Horáček JM; Cetkovský P; Mayer J; Trka J; Doubek M;
    Br J Haematol; 2022 Feb; 196(3):706-710. PubMed ID: 34816424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].
    Hirabayashi S; Manabe A; Ohki K; Kiyokawa N
    Rinsho Ketsueki; 2023; 64(7):633-638. PubMed ID: 37544723
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort.
    Zaliova M; Stuchly J; Winkowska L; Musilova A; Fiser K; Slamova M; Starkova J; Vaskova M; Hrusak O; Sramkova L; Stary J; Zuna J; Trka J
    Haematologica; 2019 Jul; 104(7):1396-1406. PubMed ID: 30630978
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma.
    Lee WJ; Moon HR; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
    J Am Acad Dermatol; 2014 Feb; 70(2):318-25. PubMed ID: 24314877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.